1714088-51-3

Telisotuzumab vedotin (Teliso-V) is an antibody drug conjugate that targets the MET receptor.

Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used to study non-small cell lung cancer expressing c-Met protein[1][2].

In the first in-human phase I trial for Teliso-V, NSCLC patients with MET-overexpressing tumors received monotherapy. The results of this innovative trial indicated favorable safety and tolerability responses and also showed promising antitumor activity in NSCLC patients with MET overexpression.

[1] Strickler JH, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. DOI:10.1200/JCO.2018.78.7697
[2] Camidge D R, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein–expressing non–small-cell lung cancer. Journal of Clinical Oncology, 2023, 41(5): 1105-1115. DOI:10.1200/JCO.22.00739